May 30, 2024 - May 28th is The International Day of Action for Women’s Healthcare to raise awareness for diseases and conditions that affect women’s physical and emotional health. The Journal of Medicinal Chemistry published a special Collection and showcased 17 articles that address the ongoing research dedicated to the unmet medical needs in women’s healthcare. TenNor’s article “Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens” was chosen for inclusion in the Collection and recognized in advancing research in women’s healthcare.

Rifasutenizol (TNP-2198) is a novel dual-acting drug candidate currently under clinical development by TenNor Therapeutics for the treatment of microaerophilic and anaerobic bacterial infections, including H. pylori infection, bacterial vaginosis, and C. difficile infection.

Bacterial vaginosis (BV) is the most common vaginal problem for women, with an estimated prevalence of 30 ~ 50%. It is caused by an overgrowth of harmful, predominantly anaerobic, bacteria in the vagina, and the resultant imbalance between ‘good’ and ‘bad’ bacteria. As antibiotic resistance becomes increasingly problematic, the effectiveness of antimicrobial treatments for BV is declining, resulting in higher recurrence rates and a significant unmet clinical need. Rifasutenizol, with its unique multi-targeting synergistic mechanism, shows potential advantages in the treatment of BV by overcoming resistance and preventing recurrence.

Collection Link: https://pubs.acs.org/page/jmcmar/vi/womens-health?ref=feature.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com